Research programme: diabetes therapy - Transition Therapeutics

Drug Profile

Research programme: diabetes therapy - Transition Therapeutics

Alternative Names: TT-402

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer Transition Therapeutics
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
  • 24 Nov 2011 The programme is in active development
  • 08 Mar 2010 Preclinical trials in Diabetes mellitus in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top